Novo Nordisk hits $500 billion in market value as it flags soaring demand for Wegovy, Ozempic
KEY POINTS
- The maker of weight loss drug Wegovy and diabetes drug Ozempic reported an increase in sales of 31% in Danish kroner and 36% at constant exchange rates to 232.3 billion kroner ($33.71 billion).
- The 2023 results were fueled by strong performance in the company’s diabetes and obesity care division, with the latter in particular soaring by 154% at CER to 41.6 billion kroner.
- Novo’s valuation rose to $506 billion at 08:06 GMT, according to CNBC’s calculation of LSEG data.
Novo Nordisk Workers Celebrate
